No Increase in Major Cardiac Events With Testosterone-Replacement Therapy
CHICAGO — Testosterone-replacement therapy was noninferior to placebo in the occurrence of major adverse cardiac events among men with hypogonadism and established or high risk for cardiovascular disease, the randomized TRAVERSE trial showed. At a mean follow-up of 33 months, the primary cardiovascular endpoint — first occurrence of any component of a composite of death […]